Becton, Dickinson and Company reports developments for a global medical technology business organized around medical essentials, connected care, biopharma systems and interventional products. Company news commonly covers fiscal results, guidance, dividends, share repurchases, debt retirement, executive appointments and strategy updates following the completed separation of the Biosciences and Diagnostic Solutions business.
BD updates also include product and customer developments across its care-delivery platforms. Recent themes include the BD® CentroVena One™ Insertion System for central venous catheter placement, BD Pyxis™ Pro medication dispensing technologies, BD Alaris™ Infusion Systems, vascular access products, medication management, patient-safety workflows and partnerships with health systems.
BD (Becton, Dickinson and Company) announced that the FDA granted Emergency Use Authorization (EUA) for its rapid SARS-CoV-2 diagnostic test using the BD Veritor™ Plus System. This test provides results in just 15 minutes, enhancing COVID-19 diagnostic access at various healthcare settings. BD plans to produce up to 2 million tests weekly by September 2020. The Veritor™ Plus System is already operational in over 25,000 locations across the U.S. The company has also delivered millions of COVID-19 related products and intends to pursue further regulatory clearances.
BD (Becton, Dickinson and Company) will host a live webcast for its third fiscal quarter 2020 earnings conference call on August 6, 2020, at 8:00 a.m. ET. A press release containing details on the quarter's earnings will be issued earlier that morning. The webcast and accompanying slides will be available on BD's investor website, with a replay option until August 13, 2020.
As a leading global medical technology company, BD focuses on enhancing health care through innovative solutions and partnerships worldwide.